|
|
|
| Analysis of Leukemia-associated Immunophenotype and Clinical Features in AML patients with FLT3-ITD Positive Expression |
| ZHOU Ying, LIU Ting, YAN Xiang-hong |
| Changsha Central Hospital , Changsha Hunan 410004,China |
|
|
|
|
Abstract 【Objective】To investigate the leukemia-associated immunophenotype (LAIP) and clinical features in acute myeloid leukemia (AML) with positive Fms-like tyrosine kinase 3-internal tandem repeat (FLT3-ITD) expression. 【Methods】A total of 206 patients with acute myeloid leukemia admitted to our hospital from March 2016 to March 2020 were selected as the study subjects. Patients were divided into the FLT3-ITD positive expression group (43 cases) and the FLT3-ITD negative expression control group (163 cases) according to the mutation status of FLT3-ITD gene. Clinical data and LAIP of the two groups were retrospectively analyzed. The survival of two groups and the outcome of one course of chemotherapy were compared between the two groups to evaluate the value of FLT3-ITD positive expression in AML patients. 【Results】The patients in the FLT3-ITD positive group had higher CD56, CD11b, CD7 and CD33 expressions than those in the FLT3-ITD negative control group, while their CD34 and CD117 expression levels were lower than those in the control group (P<0.05). The disease-free survival rate and overall survival rate of the positive group were lower than those of the control group (P<0.05). The remission rate of the positive patients was lower than that of the control group (41.86% vs 80.37%, P<0.05). The cell antigen expression rate of the patients in the complete remission group was lower than that in the non-remission group (P<0.05). 【Conclusion】FLT3-ITD gene positive AML patients have antigen differentiation disorder on the surface of leukemia cells, low remission rate and poor prognosis. The expression of FLT3-ITD gene and LAIP in AML patients are of great significance for clinical guidance of treatment and prognosis judgment.
|
|
Received: 06 December 2021
|
|
|
|
|
|
[1] 刘彦, 克晓燕, 王晶,等. 伴FLT3-ITD突变的急性髓系白血病的临床特征和预后[J].中国实验血液学杂志, 2018,26(2):354-358.
[2] 姜艳红.FLT3-ITD基因突变型和野生型初治原发急性髓细胞白血病的临床特征[J].实用医学杂志,2017,55(1):15-20.
[3] 刘筱姝,龙慧.索拉非尼联合小剂量阿糖胞苷治疗FLT3+复发、难治性急性髓系白血病临床研究[J].中国实验血液学杂志,2016,24(2):394-398.
[4] CHAUHAN P S, IHSAN R, SINGH L C, et al.Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features[J].Dis Markers,2013, 35 (5) :581.
[5] 沈悌,赵永强.血液病诊断与疗效标准[M].第4版.北京:科学出版社,2018:91-93.
[6] 尹青松.索拉非尼联合化疗一线治疗FLT3-ITD突变阳性急性髓系白血病的临床对照研究[J].中华血液学杂志,2017,38(5):415-420.
[7] 中美联合上海市白血病协作组.468例急性白血病患者FLT3基因突变及其预后价值分析[J].中华血液学杂志, 2010, 31 (1) :1-5.
[8] 徐媛媛,高丽.急性髓系白血病中FLT3-ITD基因突变的检测及其临床意义[J].中国实验血液学杂, 2012, 20 (6) :1312.
[9] 陈姣.急性髓系白血病FLT3-ITD基因突变分析[J].中国病理生理杂志,2018,30(2):241-242.
[10] 孙玲玲, 孙佳英. FLT3-ITD突变的急性髓系白血病免疫表型及临床特征分析[J].中国现代医学杂志, 2019, 29(12):58-62.
[11] 江伟,高玉娟,苏雁华.急性髓系白血病中FLT3基因突变的研究进展[J].临床与病理杂志,2020,40(3):202-206.
[12] 王伟伟,徐元宏.免疫表型及非髓系分化抗原表达分析:对急性髓细胞白血病的诊断和预后判定有应用价值[J].南方医科大学学报,2020,30(18):2442-2445. |
|
|
|
2022, Vol. 39 
